Methylphenidate for prison inmates with ADHD: yes or no?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36263739.
- Also identified by DOI 10.1192/bjp.2022.139.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a double-blind randomised controlled trial by Asherson et al., involving prisoners with attention-deficit hyperactivity disorder (ADHD), the rates of response to osmotic-release oral system methylphenidate (OROS-methylphenidate) and placebo were very similar (~50%). I critically discuss this trial against other international literature, highlighting the key issues in the field in terms of clinical practice and research.
Medical subject headings
- Attention Deficit Disorder with Hyperactivity
- Central Nervous System Stimulants
- Methylphenidate
- Prisoners